The ink is tranquillize wet from a new deal just announced between CGM-maker Dexcom and data analytics giant Google, in which they'll cooperate to develop next-generation diabetes technology.

Yep, on Tuesday morning, Dexcom and Google Life Sciences went public with their unweathered partnership that was finalized after 1am EST, with a quickly organized investor and media conference call scheduled for the early morning hours.

The press release says they'll "developa series of side by side-generation CGM products that are designed to be smaller and less expensive than alive technologies. These new products volition incorporate Google's miniaturized electronics platform with Dexcom's best-in-class sensor technology. This collaboration also provides an chance to better utilize the data generated by these CGM products to significantly improve the outcomes and reduce the costs associated with diabetes care."

Dime-Pig-sized & Fluid

Piece it's besides early to puzzle over the companies to nail down product specifics, they are foreshadowing a microscopic, flexible, bind-like and dime-squirrel-sized CGM unit that will beryllium integrated with Google's mini electronics succeeding-gen tech. The hope is for this to atomic number 4 disposable, lower-cost and thirster wear for at least 10-14 days, according to Dexcom CEO Kevin Sayer's comments on the conference call.

And with Dexcom already pushing severally to depress toll and make its CGM detector tech available in pharmacies crossways the nation, this compact device that incorporates vector and sensor, and communicates in real time to any smartphone to share data, power be something we could weft up at our topical Walgreens or CVS in the approaching age. Wow!

Of course we're tiptop curious to listen more than almost how this future D-tech will integrate with the Google Agree platform (a response to Apple's HealthKit as a central hub for health data and apps), much care Dexcom's own iOS-friendly SHARE system full treatmen with the Orchard apple tree weapons platform.

We cognize that Dexcom's been pushing for Thomas More data-sharing capability and just fresh hired a new senior data enforcement to focus along that path. Along its recent remuneration call, the company mentioned that we could expect much news later in 2015 happening its SweetSpot information-unselfish platform that was initially noninheritable back in 2012. What happens with all that now, with this new Google Life Sciences partnership, corpse to be seen.

Changing the World

No more weigh how you slice IT, this is HUGE news, as Google is of naturally an Internet Giant, and has a track track record of dynamic the globe — which information technology's now poised to do in the realm of diabetes!

"We couldn't constitute Sir Thomas More excited or so this game-changing partnership, to develop find technologies to change the subsequent of diabetes management eternally. Working together, we believe we can introduce products that testament go us beyond our core type 1 patronage to get on the standard of care for all the great unwashe living with diabetes," Sayer aforesaid on the conference call.

This hot deal comes righteous a day after Google declared a corporate restructuring, forming a new company known as Alphabet to operate as the bring up party for all of Google and its separate smaller businesses and divisions, like the Life Sciences/Google X division today working wtih Dexcom.

"Google is good at miniaturizing components, they can amaze in that location and go there faster than we ass," Sayer says. "We are very good at sensors and algorithms, and we're good at customers and taking give care of patients. At end of the day, a spouse like Google accelerates us and gives us admittance to new tech quicker than we could get this ourselves."

Dexcom sees this as a way to expand the CGM market, with the more attractive consumer-warm form factor non solely seductive more character 1 customers but also making headway into the type 2 diabetes population and allowing Dexcom to amended integrate into hospital settings and also the physiological condition diabetes residential area, Sayer says. The lower-cost and potential reimbursement aspects of this could be huge for bridging that disruption to more type 2s and even getting Medicare reportage.

Sayer says the first many-sided intersection could equal commercialized in the next two or three years, followed by a second-generation Dexcom-Google offer about five years away. Of path, none of that timeline is finalized and could always slip as this partnership moves forward.

And yes, the abstract photos of this flavour pretty red cent cool!!

Share on Pinterest

Dexcom Pipeline, Google IP

Notice that Dexcom says it will persist in work connected its up-to-date product pipeline alongside this new pretend with Google. That means they will go off ahead with near-term plans for improved sensors, including the G5 that is already subordinate review by FDA and potential to atomic number 4 authorised away year's end, and the eventide more accurate G6 sensor expected to go to FDA onetime in 2016.

The unweathered exclusive partnership gives Dexcom access code to some coveted Google intellectual property (IP), although Dexcom confirms that does non admit the cool Google glucose monitoring contact lenses announced back in early 2014 and received a patent in April 2015.

Dexcom says it will stay in charge of developing and selling the new CGM detector technical school, while the two companies leave engage in joint steering, development, and coordination activities to oversee aspects of this partnership.

There is zero immediate timeline happening whatever R&ere;D and the companies are just source to talk more in-depth about the financials and R&D resources needed, but Dexcom says they bequeath equal committing square pecuniary resource to this partnership, to top future objective trials and developing inexperienced data analytics platforms. Financially, Dexcom will also be giving Google up-front fees in the form of ordinary shares, and will make milestone payments to Google in Johnny Cash or stock as time goes on. Eventually, once products are commercialized, royalties will also be paid to Google based on value.

Big Data Learnings

On the media shout out, Sayer made an absorbing — yet kind of Magnanimous Brother — point about how information could Be examined and analyzed from these future devices, expanding on what Dexcom has already started doing with its Dexcom SHARE system. Patient data could be analyzed to learn more about patient behavior, e.g. how and when somebody with typewrite 2 actually moves to insulin-dependence.

"At what point does someone change all over to insulin and why? We wear't know," Sayer said. "But if that person was on sensors and monitored, we could maybe catch admonition signs Beaver State know how and why this happens."

It's pretty amazing to see this deal close — a small, entrepreneurial diabetes device company conjugation with a powerhouse like Google to help revolutionize information-sharing and wearables in diabetes. Kudos to Dexcom for its already-stellar batting order of joint development partnerships with pump companies, Tidepool and even Apple with the Orchard apple tree Watch Dexcom app, and for being willing to essentially "reach across the aisle" and go with Google to expand its reach in that respect.

Very exciting multiplication, and with Dexcom's credit that increased memory access and lower-cost are priorities, we have a lot to look forward to!